how many people are on glp-1 drugs in the us Products - Data Briefs - Number 537 6 facts about obesity and
Description
Bone 81, 459467
J Biol Chem 289: 2723527245, 2014
Liraglutide modulates gut microbiome and attenuates nonalcoholic fatty liver in db/db mice
doi: 10.1523/JNEUROSCI.0529-11.2011 [DOI] [PMC free article] [PubMed] [Google Scholar] 66
Eli Lilly earlier this year gained the majority share of the market thanks to its blockbuster obesity injection Zepbound, which has shown to be more effective than Novo Nordisk's Wegovy
With more to offer than just blood sugar management, GLP-1s have become popular with health care providers and the public alike
